Marea Therapeutics Presents Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93rd EAS Congress
MAR001, a first-in-class monoclonal antibody targeting ANGPTL4, demonstrated approximately 53% placebo-adjusted mean reduction in remnant cholesterol and placebo-adjusted mean reduction in triglycerides at 12 weeks
Approximately 65% placebo-adjusted mean reduction in remnant cholesterol and triglycerides in participants with greater triglyceride elevation at baseline (≥200 mg/dl)
MAR001 was generally well tolerated; Phase 2b study expected to initiate in second quarter of 2025
Second oral presentation at EAS describes association of remnant cholesterol levels with major cardiovascular events in patients with atherosclerotic cardiovascular disease, underscoring potential of MAR001 to become an important new therapeutic option
SOUTH SAN FRANCISCO, Calif., May 07, 2025--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today presented positive data from a Phase 2a clinical trial of MAR001 in a late-breaking oral session at the 93rd European Atherosclerosis Society (EAS) Congress being held May 4-7, 2025 in Glasgow, UK. MAR001 is a first-in-class monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue.
"We are very excited by these data from our Phase 2a study, which demonstrate the strong potential of MAR001 to address the most important unaddressed lipid and metabolic drivers of atherosclerotic cardiovascular disease in high-risk patients," said Josh Lehrer, M.D., M.Phil., FACC, chief executive officer of Marea. "We look forward to advancing MAR001 into Phase 2b development for treating residual cardiovascular risk in patients who remain at highest risk despite aggressive standard of care therapies."
"Atherosclerotic cardiovascular disease patients with elevated remnant cholesterol remain at an increased risk for major adverse cardiovascular events despite best available standard of care therapies," said Ethan Weiss, M.D., chief scientific officer of Marea. "These data clearly validate the ability of MAR001 to significantly lower remnant cholesterol and triglycerides by inhibiting ANGPTL4, supporting genetic findings and expected translation to substantial cardiovascular disease risk reduction. We believe MAR001 has the potential to become an important new therapeutic option for patients."
Presentation Highlights:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating
Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy rating and a $8 price target, on June 4. The analyst gave the optimistic rating due to the company's VAFSEO product and its potential in the CKD anemia market. VAFSEO is an approved treatment for anemia in adults with chronic kidney disease on dialysis. According to the analyst, the treatment is gaining considerable momentum among dialysis organizations, and this trend is anticipated to support near-term growth. He expects VAFSEO's ongoing launch to offset the effect of generics on AURYXIA, another product by Akebia Therapeutics, Inc. (NASDAQ:AKBA) that deals with hyperphosphatemia. A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics. The analyst also reasoned that Akebia Therapeutics, Inc. (NASDAQ:AKBA) is positioned for success as it has secured contracts that cover almost all dialysis patients in the US. VAFSEO offers flexibility in its dosing regimen, ranging from 150mg to 600mg, making it a factor that allows for personalized treatment and potentially growing prescriptions. Caufield pointed out VAFSEO's oral administration as another reason supporting the optimistic rating, giving it an advantage over existing therapies, such as iron supplementation and erythropoiesis-stimulating agents. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company that develops and commercializes drugs to treat metabolic and renal diseases. While we acknowledge the potential of AKBA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
7 hours ago
- Yahoo
Uptick in tick bites reported in Central Pennsylvania emergency rooms
JOHNSTOWN, Pa. (WTAJ) — With summer temperatures reaching Central Pennsylvania, emergency rooms are noticing an uptick in ticks. 'The seasons are now changing and so we're doing a lot more outdoor stuff,' said Nsikak Daniel, M.D., an emergency room physician at Conemaugh Memorial Medical Center in Johnstown. 'Ticks are just one of those things you kind of get when you go out into the woods.' While children and older adults may have the most adverse reactions to tick bites, everyone should take precautions. Juniata College receives approval from state nursing board for new nursing program 'Wear clothing that covers you up, you know, socks and stuff like that with your shoes. Insect repellents sometimes can help,' Daniels said. Lyme Disease is a common illness carried by ticks, often characterized by a bullseye–shaped rash around a bite. While it's become more prevalent, Daniels said it's not the only thing you should worry about. 'One of the complications a lot of people don't think about is something that's called anaplasmosis. It's a very serious, tick borne illness and it's something that can affect your bloodstream. It can affect your organs and cause organ damage,' Daniels said. If you get bit and have any concerns that you did not remove the tick or notice signs of infection such as fever or a rash, you should go to the emergency room immediately. Veterinarians also said they're seeing a rise in bites and infections in dogs. They said the best way to keep your furry friend safe is to use medications and repellents, mow your lawn and avoid high risk areas like tall grass and wooded areas during tick season. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
7 hours ago
- Yahoo
Fourth annual Hallie Grace Memorial Butterfly Ball for EB
SAVANNAH, Ga. (WSAV) — Epidermalysis Bullosa, also known as EB, is a rare genetic condition that affects one in every 20,000 births. Babies diagnosed with this condition usually don't live long lives, and they are often referred to as butterfly babies because their skin is as fragile as a butterfly's wings. Turning grief into triumph is how one family, whose child was diagnosed with a rare genetic skin condition, is honoring her life and legacy. 'To be a lost parent is the worst thing in the world. And I would give anything to make sure nobody else has to ever go through that again,' said mother of Hallie Grace and Executive Director of Heroes for Hallie Grace, INC Anne Davis. It's the fourth annual Hallie Grace Memorial Butterfly Ball for EB. Mom of Hallie Grace Anne Davis, who passed away when she was only three months old from the genetic skin condition, said events like these are important to spread awareness because many don't know what EB is or how it affects families dealing with it. 'When you lose a child, the one thing you want more than anything is for them to be remembered and to know that their life mattered,' Davis said. 'So, our biggest mission, is that we raise awareness, we raise funding all that. But our biggest thing is connecting with the families, making sure that those families know that those children still matter, whether or not they're still here.' The painful skin condition is caused by a missing protein that holds the skin together, so with any sort of touch or heat, it can blister the skin and cause it to fall off. Davis said when doctors told her there was nothing they could do; she made it a goal to make sure another family would never have to experience the pain that they felt that day. 'When we get to know these families and we get to see these families go through this and we know what the diagnosis is, it's like watching a Mack truck going to hit someone and not being able to stop it, and so our goal with everything that we do is to stop it,' Davis said. In the three years that Davis and her family have been advocating, there have been medical breakthroughs, now she said they are just waiting for a cure. 'I remember thinking, how do we have nothing,' Davis said. 'Since that time, so in just over a couple of years, we have three approved treatments for EB, two of which could actually work for Hallie's type, depending. But we're getting there. I mean, we're making huge, incredible strides. The FDA has approved these things, so now people don't have to hear there's nothing we can do.' There are only a few tickets left for tonight's ball. If you're interested in purchasing those or just learning more about EB and the heroes for Hallie Grace organization, you can click or tap here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
